CTCs and ctDNA were then analysed using Illumina's customised 79 gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. In the patients that had not received any ...
Over the last six months, Angle has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...
CTCs and ctDNA were then analysed using Illumina's customised 79 gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. In the patients that had not received any ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback